Literature DB >> 33960936

Preoperative Alpha-Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma in Non-Cirrhotic Patients After Surgical Resection.

Tian-Ming Gao1, Dou-Sheng Bai2, Jian-Jun Qian2, Ping Chen2, Sheng-Jie Jin2, Guo-Qing Jiang2.   

Abstract

BACKGROUND: Alpha-fetoprotein (AFP) has been widely used as a tumor marker in the treatment of hepatocellular carcinoma (HCC) in patients with cirrhosis. However, a large number of HCC patients are diagnosed without cirrhosis, and the prognostic capability of AFP was unclear in HCC patients without cirrhosis. Our purpose was to investigate the prognostic efficiency of AFP in patients with non-cirrhosis, single, and small HCC who were treated with surgical resection.
METHODS: Among the 111 374 liver cancer patients included in the Surveillance, Epidemiology, and End Results database, we selected 224 patients without cirrhosis with a single HCC ≤3 cm in diameter who were identified at diagnosis and treated with surgical resection. The AFP test results were recorded as AFP-positive and AFP-negative levels.
RESULTS: Kaplan-Meier method showed that there was no significant survival difference between the AFP-positive and AFP-negative groups (P = .566). The same results were found in the subgroups of patients with tumor size ≤2 cm and 2-3 cm (P = .710 and .687, respectively). Receiver operating characteristic (ROC) curve analysis showed that AFP had inadequate accuracy to discriminate survivors and deceased patients in subgroups of patients with tumor size ≤3 cm, 2-3 cm, or ≤2 cm (area under the ROC curve = 0.449, 0.458, 0.443; 95% confidence interval = 0.366-0.533, 0.346-0.571, 0.317-0.569, respectively).
CONCLUSION: AFP levels have no predictive value in well-compensated non-cirrhosis patients with single, small HCC (≤3 cm) treated with surgical resection for curative intent.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33960936      PMCID: PMC8975432          DOI: 10.5152/tjg.2020.20156

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  31 in total

1.  Role of the model for end-stage liver disease and serum alpha-fetoprotein as prognostic predictors for hepatocellular carcinoma.

Authors:  Teh-Ia Huo; Shou-Dong Lee
Journal:  Liver Int       Date:  2006-12       Impact factor: 5.828

2.  Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.

Authors:  Edoardo G Giannini; Simona Marenco; Giacomo Borgonovo; Vincenzo Savarino; Fabio Farinati; Paolo Del Poggio; Gian Ludovico Rapaccini; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

3.  Trends in primary liver cancer.

Authors:  S Deuffic; T Poynard; L Buffat; A J Valleron
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

4.  Increase in primary liver cancer in the UK, 1979-94.

Authors:  S D Taylor-Robinson; G R Foster; S Arora; S Hargreaves; H C Thomas
Journal:  Lancet       Date:  1997-10-18       Impact factor: 79.321

5.  Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival.

Authors:  Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

Review 6.  Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients.

Authors:  F Nomura; K Ohnishi; Y Tanabe
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

7.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.

Authors:  Teh-Ia Huo; Yi-Hsiang Huang; Wing-Yiu Lui; Jaw-Ching Wu; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Oncol Rep       Date:  2004-02       Impact factor: 3.906

9.  Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.

Authors:  Hyoung Su Kim; Ji Won Park; Ji Sun Jang; Ha Jung Kim; Woon Geon Shin; Kyung Ho Kim; Jin Heon Lee; Hak Yang Kim; Myoung Kuk Jang
Journal:  J Clin Gastroenterol       Date:  2009 May-Jun       Impact factor: 3.062

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.